Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]

Cox, Helen; Ford, Nathan

doi:10.5588/ijtld.11.0451

Cited by 127 publications

(103 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…16,17 Furthermore, the OBR for many patients in the BCAP included linezolid, another drug that has shown improved culture conversion rates for XDR-TB. 18,19 These early results are encouraging for the South African NTP, which has targeted an MDR-TB success rate of 60% by 2016.…”

Section: Discussionmentioning

confidence: 72%

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis

Ndjeka

Conradie

Schnippel

et al. 2015

int j tuberc lung dis

132

100

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 72%

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis

Ndjeka

Conradie

Schnippel

et al. 2015

int j tuberc lung dis

132

100

View full text Add to dashboard Cite

“…With regard to toxicity, a reduced initial linezolid dose or a dose adjustment during treatment (e.g. using the therapeutic drug monitoring (TDM) approach) has shown to improve tolerance without affecting efficacy [30,36,[39][40][41][42]. In fact, adverse events are lower when a linezolid dose of 300 mg·day −1 is used [40].…”

Section: Linezolidmentioning

confidence: 99%

Classification of antituberculosis drugs: a new proposal based on the most recent evidence

Caminero

Scardigli

2015

Eur Respir J

View full text Add to dashboard Cite

@ERSpublicationsThe classification of the anti-TB drugs should probably be modified to optimise the use old and new compounds http://ow.ly/QbDSP Multidrug-resistant (MDR) tuberculosis (TB) (resistance to at least isoniazid and rifampicin), with >480 000 cases in 2013, 10% of them being affected by extensively drug-resistant (XDR)-TB (MDR-TB with additional resistance to any fluoroquinolone, and to injectable second-line drugs (SLDs) (capreomycin, kanamycin or amikacin)), continues to represent a real threat to TB control [1][2][3][4]. In some high MDR-TB burden countries, the prevalence of MDR-TB among new cases exceeds 20% and among retreatment cases, reaches almost 50% [1,5].Prevention and quality diagnosis and treatment of MDR-and XDR-TB are part of the crucial interventions included in Pillar 1 of the new World Health Organization (WHO) End TB Strategy, which is focussed on the goal of TB elimination [6][7][8]. Unfortunately, the outcomes of these cases are suboptimal, with 60% success among MDR-TB cases [2], 40% among XDR-TB cases [3] and <20% among the cases with resistance patterns beyond XDR-TB [4]. This means not only high mortality but also significant human suffering and transmission of the Mycobacterium tuberculosis strains within the community [9]. Unfortunately, at present, the treatment of MDR/XDR-TB is still very long, toxic and expensive [10,11].The original WHO guidance on the management of MDR-TB was issued in 1996 [12] and since then, several updated guidelines have been published. The fundamentals on MDR/XDR-TB treatment were published in the 2006 and 2008 WHO guidelines [13,14], where the basic rationale to design therapeutic regimens for these cases was described. According to these recommendations, which are currently followed worldwide, the anti-TB drugs are classified into five main groups indirectly considering the evidence available, the safety and/or the effectiveness of the different drugs. These groups start from the most effective drugs (group 1), grouping the other drugs progressively according to decreasing order of efficacy [15].In the 2011 revision of the WHO MDR/XDR-TB guidelines [16], the composition of different groups of anti-TB drugs was not modified. Therefore, since 2006, the rationale of the classification of the anti-TB drugs has not been changed but several studies have examined the effectiveness, efficacy and safety of the group 5 drugs, and some of these drugs appear to be more effective and well tolerated than others that currently have "higher" ranking in the classification. Furthermore, promising new drugs active against M. tuberculosis have been discovered in the last couple of years [17][18][19][20] and have become progressively available in many parts of the world to treat MDR/XDR-TB.

show abstract

“…Ek olarak linezolid kullanan hastalarda "kırmızı adam sendromu", kaşıntı ve döküntü gibi yan etkilerin daha az olduğu bununla birlikte trombositopeni ve mide bulantısının ise daha fazla olduğu gözlenmiştir (5) . Benzer şekilde; 11 çalışmanın incelendiği metaanalize göre (n=148), dirençli tüberküloz tedavisinde linezolidin başarı oranı %68, çok ilaca dirençli tüber-küloz (MDR-TB) tedavisinde ise %62 bulunmuştur (6) . MDR-TB tedavisinde %92.5'e varan düzeyde başarı oranları bildirilmiştir (7) .…”

Section: Yeni Antibiyotiklerunclassified

New antibiotics

Acar¹,

Somer²,

Salman³

2016

Cocuk Dergisi

View full text Add to dashboard Cite

GirişBirleşik Devletler Hastalık Kontrol Merkezine (Center for Disease Control, CDC) göre, her yıl yaklaşık olarak iki milyon kişi antibiyotikler tarafından tedavi edilemeyen bakterilerce enfekte olmakta ve bunların 23.000 kadarı yaşamını kaybetmektedir. Özellikle yoğun bakım üniteleri, hematoloji-onkoloji servisleri ve transplantasyon merkezleri gibi yüksek riskli hasta popülasyonunun bulunduğu klinikler dirençli mikroorganizma enfeksiyonlarının tehdidi altındadır. Son yıllarda, yeni antibiyotik gelişimi üze-rine yapılan çalışmalar, kanser tedavisi, aşı çalışma-ları, kolesterol düşürücü ilaçlar gibi farmakolojinin diğer alanlarıyla kıyaslandığında yetersiz kalmaktadır. Piyasaya sürülen antibiyotikler, yeni molekülle-rin keşfinden ziyade sıklıkla, eski antibiyotiklerin türevleri şeklindedir. Bu makalede, geçtiğimiz yıllar-da klinik kullanıma sunulan ve hâlen önemini koruyan linezolid, dirençli mikroorganizmaların artış göstermesi ile kullanım sıklığı artan tigesiklin ve henüz ülkemizde kullanıma girmemiş olan seftarolinin farmakolojik özellikleri ve klinik endikasyonları derlenmiştir. LinezolidOksazolidinon sınıfı antibiyotiklerin ilki olan linezolid, Yeni AntibiyotiklerManolya AcAr*, Ayper Somer*, Nuran SAlmAn* Çocuk Dergisi 15(3-4):99-103, 2015

show abstract

Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]

Cited by 127 publications

References 30 publications

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis

Classification of antituberculosis drugs: a new proposal based on the most recent evidence

New antibiotics

Contact Info

Product

Resources

About